Contrasting Ardelyx (NASDAQ:ARDX) & Bioasis Technologies (OTCMKTS:BIOAF)

Ardelyx (NASDAQ:ARDX) and Bioasis Technologies (OTCMKTS:BIOAF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Volatility & Risk

Ardelyx has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Bioasis Technologies has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.

Insider & Institutional Ownership

58.9% of Ardelyx shares are owned by institutional investors. 4.8% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for Ardelyx and Bioasis Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1	1	9	2	2.92
Bioasis Technologies	0	0	0	0	0.00

Ardelyx currently has a consensus target price of $11.64, suggesting a potential upside of 100.32%. Given Ardelyx’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Ardelyx is more favorable than Bioasis Technologies.

Profitability

This table compares Ardelyx and Bioasis Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ardelyx	-14.60%	-36.57%	-13.42%
Bioasis Technologies	N/A	N/A	N/A

Earnings & Valuation

This table compares Ardelyx and Bioasis Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$386.15 million	3.63	-$39.14 million	($0.23)	-25.26
Bioasis Technologies	N/A	N/A	N/A	($0.02)	-0.01

Bioasis Technologies has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Bioasis Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Ardelyx beats Bioasis Technologies on 8 of the 13 factors compared between the two stocks.

About Ardelyx

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

About Bioasis Technologies

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.